


## **SUPPLEMENTAL MATERIAL**

**Supplemental Figure 1.** Study schema.

**Supplemental Table 1.** Changes in exploratory and safety outcome measures in those randomized to ferric citrate vs. ferrous sulfate for 12 weeks.

## Supplemental Figure. Study schema



**Supplemental Table 1.** Changes in exploratory and safety outcome measures in those randomized to ferric citrate vs. ferrous sulfate for 12 weeks.

	Baseline values, mean (SD)		12-week change from baseline, mean estimate (95% CI)			
	Ferrous sulfate	Ferric citrate	Ferrous sulfate	Ferric citrate	Difference	<i>P-value</i>
PTH, pg/ml	135 (81)	129 (69)	1 (-24,25)	-5 (-19,10)	7 (-20,34)	0.62
Phosphorus, mg/dL	4.0 (0.9)	3.7 (0.5)	-0.0 (-0.3,0.2)	-0.1 (-0.4,0.1)	-0.1 (-0.2,0.4)	0.52
ERFE, pg/ml	1.4 (0.4)	0.9 (1.4)	-0.3 (-0.9,0.2)	-0.3 (-1.4,0.8)	0.0 (-1.1,1.1)	0.98
IL-6, pg/ml	2.4 (1.9)	1.7 (1.0)	-0.0 (-0.4,0.4)	1.2 (-0.1,2.5)	1.2 (-0.2, 2.6)	0.08
IFN, pg/ml	33 (67)	14 (7)	-18 (-48,12)	7 (-4,18)	25 (-5,54)	0.10
IL-10, pg/ml	0.4 (0.3)	0.3 (0.3)	0.0 (-0.1,0.1)	0.1 (-0.0,0.2)	0.1 (-0.1,0.3)	0.27
TNF, pg/ml	3.1 (1.0)	2.6 (0.8)	-0.1 (-0.4,0.1)	0.1 (-0.2,0.4)	0.2 (-0.2,0.6)	0.23
IL-22, pg/ml	1.2 (1.2)	0.7 (0.7)	1.2 (-0.5,2.9)	0.1 (-0.4,0.6)	-1.0 (-2.7,0.6)	0.19

Abbreviations: PTH, parathyroid hormone; ERFE, erythroferrone; IL, interleukin; IFN, interferon- $\gamma$ ; TNF, tumor necrosis factor- $\alpha$